Refine
Year of publication
Has Fulltext
- yes (1115)
Is part of the Bibliography
- no (1115)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Beauty production (2)
- Bevorratung (2)
- COVID-19 (2)
- Cancer (2)
- Charm physics (2)
- Diagnostik (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Heart failure (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Quality of care (2)
- Quasi-free scattering (2)
- Relativistic heavy-ion collisions (2)
- Rheumatoid arthritis (2)
- Richtlinie (2)
- SARS-CoV-2 (2)
- Seizure (2)
- Shell model (2)
- Single electrons (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 900 GeV (1)
- ABS (1)
- ALICE detector (1)
- ALK (1)
- Abusive head trauma (AHT) (1)
- Africa (1)
- Afrika (1)
- Anatomic competence (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Antibiotic stewardship (1)
- Anticonvulsant (1)
- Antimicrobial resistance (1)
- Aortic valve (1)
- Apoptosis (1)
- Artesunate (1)
- Arthroscopy (1)
- Asia (1)
- Asien (1)
- Atherosclerosis (1)
- BESIII (1)
- Bayesian inference (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Biological control (1)
- Blood pressure (1)
- Body mass index (1)
- Boosted Jets (1)
- Brain tumors (1)
- Branching fractions (1)
- CHEPs (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Capsaicin (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardiology (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cerebral toxoplasmosis HIV (1)
- Charge fluctuations (1)
- Children and adolescents (1)
- Chronic obstructive pulmonary disease (1)
- Clinical pathways (1)
- Clinical study (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Consensus document (1)
- Costs (1)
- Cross sections (1)
- Death rates (1)
- Depression (1)
- Diagnosis (1)
- Differential diagnosis (1)
- Direct nuclear reactions (1)
- Direct reactions (1)
- D⁰ meson (1)
- Education (1)
- Ejection fraction (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Emotions (1)
- Endothelial cells (1)
- Europe (1)
- Everolimus (1)
- Exercise training (1)
- Experimental models of disease (1)
- Falciparum (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Forschung (1)
- Genetics (1)
- Genomic instability (1)
- Guideline (1)
- HBT (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- HIV (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronic decays (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Head and neck Cancer (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- High-energy neutron detection (1)
- Idiobiont (1)
- Implantable cardioverter-defibrillator (1)
- Inclusive spectra (1)
- Inflammation (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Inverse kinematics (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Knee joint (1)
- Koinobiont (1)
- Late presentation (1)
- Lee type, functional outcome (1)
- Lehre (1)
- Leukemia (1)
- Long non-coding RNAs (1)
- Lymphadenopathy (1)
- MTOR inhibitor (1)
- MYCN amplification (1)
- Malaria (1)
- Material budget (1)
- Medical (1)
- Mental health and psychiatry (1)
- Metabolic diseases (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular medicine (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Musculoskeletal ultrasound (1)
- NMR spectroscopy (1)
- NSAIDs (1)
- Natural product (1)
- Neural network (1)
- Non-abusive head trauma (NAHT) (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleolar protein 14 (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- ORP (1)
- One-nucleon removal (1)
- Opportunistic infections (1)
- Otorhinolaryngology (1)
- Outcomes (1)
- PAD-test (1)
- PCP (1)
- PYTHIA (1)
- Pacemaker (1)
- Palaearctic (1)
- Paleoarktik (1)
- Pancreatic surgery (1)
- Pancreatoduodenectomy (1)
- Particle and Resonance Production (1)
- Patient reported outcomes (1)
- Pb–Pb (1)
- Phospholipids (1)
- Physical activity (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Pneumocystis jirovecii (1)
- Prevention (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Protein synthesis (1)
- Proton–proton (1)
- Psychometrics (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Questionnaires (1)
- Quinine (1)
- RARP (1)
- RAS pathway (1)
- Randomized controlled trial (1)
- Rapidity Range (1)
- Rational use (1)
- Reactions with relativistic radioactive beams (1)
- Regulatory networks (1)
- Relativistic heavy ion physics (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Rhabdomyoma (1)
- Rheumatology (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- Salivary gland diseases (1)
- Sarcomas (1)
- Severe malaria (1)
- Shoulder joint (1)
- Single muons (1)
- Social participation (1)
- Sociodemographic characteristics (1)
- Specialist training (1)
- Spectroscopic factors (1)
- Spectroscopic factors & electromagnetic moments (1)
- Structured reporting (1)
- Students (1)
- Subependymal giant cell astrocytoma (1)
- Systematic Uncertainty (1)
- T-DM1 (1)
- T. pintoi (1)
- T. semblidis (1)
- TR (1)
- TSC (1)
- Teaching (1)
- Thrombosis (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Treatment (1)
- Treatment modification (1)
- Trichogramma chilonis (1)
- Trigger (1)
- Ultrasonography (1)
- University hospitals (1)
- Universitätskliniken (1)
- Vector Boson Production (1)
- Vioprolide A (1)
- Vorratsschutz (1)
- Weiterbildung (1)
- Wirtserkennung (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- acupuncture (1)
- acute coronary syndrome (1)
- acute-on-chronic liver failure (1)
- advanced breast cancer (1)
- aging (1)
- amino acid PET (1)
- animal experiments (1)
- antibiotic therapy (1)
- antihormone therapy (1)
- artificial intelligence (1)
- astroglia (1)
- biological control (1)
- biologische Bekämpfung (1)
- biologische Kontrolle (1)
- bortezomib (1)
- cART (1)
- cell-free protein synthesis (1)
- chemotherapy (1)
- clinical pathways (1)
- copeptin (1)
- cytokines (1)
- dE/dx (1)
- detector (1)
- endothelin (1)
- endothelin receptor type A antagonist (1)
- erythropoietin (1)
- exercise therapy (1)
- experimental results (1)
- gastric surgery (1)
- glioma (1)
- heavy ion experiments (1)
- high-risk neuroblastoma (1)
- host-finding (1)
- hypoxia (1)
- idiobiont (1)
- imaging (1)
- induction regimen (1)
- infections: pneumonia, TB, viral (1)
- inflammation (1)
- interferons (1)
- intranasal administration (1)
- intrinsically disordered region (1)
- kidney (1)
- koinobiont (1)
- lapatinib (1)
- lenalidomide (1)
- liver cirrhosis (1)
- liver immunology (1)
- mTOR inhibitor (1)
- macrophages (1)
- medical training (1)
- metastatic (1)
- mice (1)
- monoclonal antibody (1)
- mortality (1)
- multiple myeloma (1)
- myocardial infarction (1)
- neuroprotection (1)
- neutralizing antibody (1)
- nonstructural proteins (1)
- oncological gastrectomy (1)
- outcomes (1)
- p53 pathway (1)
- pertuzumab (1)
- quality of care (1)
- quark gluon plasma (1)
- registry (1)
- renal failure (1)
- resectability (1)
- spectra (1)
- standardization (1)
- stored grain (1)
- stored product protection (1)
- stored products (1)
- structural proteins (1)
- tension type headache (1)
- topical administration (1)
- traditional Chinese medicine (1)
- transduction (1)
- trastuzumab (1)
- treatment-related changes (1)
- troponin (1)
- tumor progression (1)
- virus (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1052)
- Frankfurt Institute for Advanced Studies (FIAS) (959)
- Informatik (924)
- Medizin (51)
- ELEMENTS (6)
- Informatik und Mathematik (3)
- Biochemie, Chemie und Pharmazie (2)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Pharmazie (2)
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Introduction: In the time of increasing resistance and paucity of new drug development there is a growing need for strategies to enhance rational use of antibiotics in German and Austrian hospitals. An evidence-based guideline on recommendations for implementation of antibiotic stewardship (ABS) programmes was developed by the German Society for Infectious Diseases in association with the following societies, associations and institutions: German Society of Hospital Pharmacists, German Society for Hygiene and Microbiology, Paul Ehrlich Society for Chemotherapy, The Austrian Association of Hospital Pharmacists, Austrian Society for Infectious Diseases and Tropical Medicine, Austrian Society for Antimicrobial Chemotherapy, Robert Koch Institute.
Materials and methods: A structured literature research was performed in the databases EMBASE, BIOSIS, MEDLINE and The Cochrane Library from January 2006 to November 2010 with an update to April 2012 (MEDLINE and The Cochrane Library). The grading of recommendations in relation to their evidence is according to the AWMF Guidance Manual and Rules for Guideline Development.
Conclusion: The guideline provides the grounds for rational use of antibiotics in hospital to counteract antimicrobial resistance and to improve the quality of care of patients with infections by maximising clinical outcomes while minimising toxicity. Requirements for a successful implementation of ABS programmes as well as core and supplemental ABS strategies are outlined. The German version of the guideline was published by the German Association of the Scientific Medical Societies (AWMF) in December 2013.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
Background and objectives: Our study aimed at examining the long-time inflammatory effects of rheumatoid arthritis (RA) as chronic immune-mediated disease on pain sensation and neuropathy development compared to healthy subjects (HS).
Methods: We used the quantitative sensory testing (QST) protocol of the German Research Network on Neuropathic Pain and Electroencephalography (EEG)–based contact heat evoked potentials (CHEPs) before and after topical capsaicin application. We recruited 16 RA patients in remission or low disease activity state (mean age: 59.38 years [± 10.18]) and 16 healthy subjects (mean age: 56.69 years [± 8.92]).
Results: The application of capsaicin cream on the thigh provoked a stronger effect in HS for both mechanical and heat pain thresholds (MPT and HPT, resp.), according to the area under the receiver operation characteristic (AUROC) (HS: HPT: 0.8965, MPT: 0.7402; RA: HPT: 0.7012, MPT: 0.6113). We observed contrary effects regarding changes in CHEPs (HS: g*max = − 0.65; RA patients: g*max = 0.72).
Conclusion: As the overall effect of topical capsaicin application was higher in HS for QST, we suggest the existence of a sensitization of TRPV1 channels in RA patients caused by long-time chronical inflammation, despite a lack of clinical signs of inflammation due to adequate treatment. The effect in CHEPs probably uncovers neuropathic symptoms. The effect of topical capsaicin on HPTs and CHEPs can act as a marker for the extent of sensitization and the development of neuropathic symptoms. Further studies are needed to prove if our proposed method can act as a marker for the success of anti-inflammatory treatment.
Long non-coding RNAs (lncRNAs) contribute to cardiac (patho)physiology. Aging is the major risk factor for cardiovascular disease with cardiomyocyte apoptosis as one underlying cause. Here, we report the identification of the aging-regulated lncRNA Sarrah (ENSMUST00000140003) that is anti-apoptotic in cardiomyocytes. Importantly, loss of SARRAH (OXCT1-AS1) in human engineered heart tissue results in impaired contractile force development. SARRAH directly binds to the promoters of genes downregulated after SARRAH silencing via RNA-DNA triple helix formation and cardiomyocytes lacking the triple helix forming domain of Sarrah show an increase in apoptosis. One of the direct SARRAH targets is NRF2, and restoration of NRF2 levels after SARRAH silencing partially rescues the reduction in cell viability. Overexpression of Sarrah in mice shows better recovery of cardiac contractile function after AMI compared to control mice. In summary, we identified the anti-apoptotic evolutionary conserved lncRNA Sarrah, which is downregulated by aging, as a regulator of cardiomyocyte survival.